Carmignac Gestion Clearside Biomedical, Inc. Transaction History
Carmignac Gestion
- $5.82 Billion
- Q3 2024
A detailed history of Carmignac Gestion transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Carmignac Gestion holds 1,933,531 shares of CLSD stock, worth $1.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,933,531
Previous 2,132,744
9.34%
Holding current value
$1.8 Million
Previous $2.77 Million
11.44%
% of portfolio
0.04%
Previous 0.05%
Shares
11 transactions
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.64 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.04 Million3.43% of portfolio
-
Black Rock Inc. New York, NY798KShares$742,2670.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$692,7460.0% of portfolio
-
Geode Capital Management, LLC Boston, MA731KShares$680,1880.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $56M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...